About Alexander Disease
Alexander disease (AxD) is a rare autosomal dominant leukodystrophy caused by mutations in the GFAP gene encoding glial fibrillary acidic protein, a major structural component of astrocyte intermediate filaments. These mutations lead to abnormal accumulation of phosphorylated GFAP and other proteins forming characteristic Rosenthal fibers—hyaline inclusions within astrocytes—and result in severe astrocyte dysfunction.
The disease causes progressive neurodegeneration affecting both white matter and gray matter structures with profound impact on motor, cognitive, and behavioral functions. The infantile form is the most severe, typically presenting before age 2 with developmental delay, seizures, and rapid progressive neurological deterioration. Megalencephaly (abnormally enlarged brain) is characteristic and may be present at birth.
The juvenile form has onset between ages 2-12 with more gradual progression and different clinical features. The adult form has the slowest progression and sometimes presents with relatively mild focal symptoms. MRI characteristically shows periventricular white matter signal changes, Rosenthal fiber accumulation predominantly in frontal regions, and progressive atrophy. The pattern of white matter involvement may help distinguish it from other leukodystrophies.
Common Symptoms of Alexander Disease
Recognizing the signs of Alexander Disease early can lead to faster diagnosis and better outcomes. Symptoms may vary in severity from person to person. If you or a loved one are experiencing any of the following, consider speaking with a specialist.
- Progressive developmental delay and cognitive decline
- Spasticity and hyperreflexia
- Ataxia and coordination problems
- Seizures
- Megalencephaly in infantile form
- Bulbar dysfunction and speech difficulties
Who Alexander Disease Affects
Alexander disease has three clinical forms with distinct age presentations: infantile form with onset before age 2 (most common and severe), juvenile form with onset ages 2-12 (intermediate severity), and adult form with onset after age 12 (slowest progression).
The condition affects males and females equally. Autosomal dominant inheritance means approximately 50% of offspring of affected parents inherit mutations, though de novo mutations account for a significant proportion of cases. Penetrance appears to be high.
Find Your Next Step
Answer a few questions and we'll point you to the right tools and information for where you are right now.
FDA-Approved Treatments for Alexander Disease
There is currently 1 FDA-approved medication for Alexander Disease. These therapies represent the current standard of care and may be used alongside or compared against investigational treatments in active clinical trials.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
Help Paying for Alexander Disease Treatment
Charity funds and drugmaker programs for Alexander Disease, checked at the source. Pick your insurance to see what fits.
- From a charity · United Leukodystrophy FoundationHultman Memorial Fund fundOpen
Pays for: Expenses directly related to the affected family member, based on demonstrated hardship (per 12 months), up to $500 per year.
The foundation says: “Applications are reviewed on a rolling basis as funding is available.”
Side Effect Explorer
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Genetic Testing
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Alexander Disease Resources
Reputable organizations and medical references for learning more about Alexander Disease, including disease registries, foundation resources, and clinical guidelines.